Risk of breast cancer among users of aspirin and other anti-inflammatory drugs by García Rodríguez, L A & González-Pérez, A
Risk of breast cancer among users of aspirin and other anti-
inflammatory drugs
LA Garcı ´a Rodrı ´guez
1 and A Gonza ´lez-Pe ´rez*,1
1Centro Espan ˜ol de Investigacio ´n Farmacoepidemiolo ´gica (CEIFE), C/Almirante 28 21, 28004 Madrid, Spain
We conducted a cohort study with a nested case–control analysis to evaluate the effect of anti-inflammatory drugs in breast cancer
incidence using the General Practice Research Database. Women taking aspirin and paracetamol for 1 year or longer had an odds
ratio (OR) of 0.77 (95 percent confidence interval (95% CI): 0.62,0.95) and 0.76 (95% CI: 0.65,0.88), respectively, compared to
nonusers. Daily doses of aspirin (75mg) and paracetamol (up to 2000mg) showed the greatest reduced risk. Use of non-aspirin
nonsteroidal anti-inflammatory drugs for more than 1 year was not associated with a reduced risk of breast cancer (OR¼1.00 (95%
CI: 0.84, 1.17), and the corresponding estimate among users with at least 2 years duration was similar. Our findings suggest that
aspirin at cardioprophylactic doses as well as paracetamol at analgesic doses is associated with a reduced risk of breast cancer.
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There is mounting epidemiological evidence suggesting that
nonsteroidal anti-inflammatory drugs (NSAIDs) may substantially
reduce the risk of colorectal cancer (Thun et al, 1991; Garcı ´a
Rodrı ´guez and Huerta-A ´lvarez, 2000). The effects of NSAIDs in
other cancers have also been extensively studied in the last decade.
Nonsteroidal anti-inflammatory drugs have been shown to prevent
breast cancer in animal models (Lala et al, 1997; Robertson et al,
1998). Proposed mechanisms commonly involve the inhibition of
cyclooxygenase-2 (COX-2) (Sjodahl, 2001), the enzyme responsible
for the production of various prostaglandins that play a key role in
the proliferation of tumour tissue; there is accumulating evidence
that NSAIDs may have the ability to restore apoptosis and inhibit
angiogenesis (Thun et al, 2002).
Observational studies of the effect of NSAIDs in breast cancer
have shown inconclusive results through a meta-analysis, includ-
ing data from 15 studies that concluded that NSAIDs could be
associated with a small decrease in risk (Khuder and Mutgi, 2001).
However, the association between breast cancer incidence and
glucocorticoid therapy has been hardly explored. Results from in
vitro studies suggest that glucocorticoids have a direct inhibitory
effect on proliferation of mammary cancer cells (Goya et al, 1993).
However, to our knowledge, this hypothesis has not been tested in
an epidemiological study.
We conducted a cohort study with a nested case control
analysis to evaluate the effect of anti-inflammatory drugs in breast
cancer incidence using the General Practice Research Database
(GPRD).
MATERIALS AND METHODS
We used data from the GPRD. This database contains computerised
information entered by general practitioners (GPs) in the UK
(Garcı ´a Rodrı ´guez and Pe ´rez Gutthann, 1998). Data on over two
million patients are systematically recorded and sent anonymously
to the Medicines and Healthcare products Regulatory Agency
(MHRA), which collects and organises this information in order to
be used for research projects. The computerised information
includes demographics, details from general practitioner’s visits,
diagnoses from specialist’s referrals and hospital admissions,
results of laboratory tests and a free text section. Prescriptions
issued by the general practitioner are directly generated from the
computer. Several studies with the GPRD have documented the
validity and completeness of this database (Jick et al, 1991).
Study population
We identified all female subjects 30–79 years old between January
1995 and December 2001. Women became members of the study
population on the first day of the study period when they met the
criteria of at least 1 year enrolment with the GP and 1 year since
the first computerised prescription. That date was their start date.
Study members with a code for cancer before start date were
excluded. We also excluded women 70 years and older at start date
with a follow-up greater than 1 year and no data recorded during
their total follow-up time: an indicator of nonassistance with their
GP. Our final study cohort comprised 734899 women.
Follow-up
All study members were followed from start date until the earliest
occurrence of one of the following end points: recorded diagnosis
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yof breast cancer, any cancer other than breast, age of 80 years,
death or end of study period (December 2001).
Case ascertainment and validation
We identified 4005 patients with a code of breast cancer and
manually reviewed their computerised patient profiles. Informa-
tion included demographic data and all clinical information with
no personal identifiers. We excluded 297 women: the main reasons
were the computer diagnosis was subsequently not confirmed
(60%) and prevalent cases (31%). A previous study validating a
large number of cancer cases documented a high reliability of
cancer diagnoses recorded in the GPRD (Jick et al, 1997). In our
study, we sent questionnaires to the GPs for validation of a random
sample of 114 cases. A total of 108 (95%) questionnaires were
received, and all of them confirmed the computer diagnosis of
breast cancer. In the end, 3708 patients were considered incident
cases of breast cancer.
Cohort and nested case–control analysis
All cases of breast cancer (n¼3708) identified in the study cohort
were used in the nested case–control analysis and we considered
their date of initial diagnosis as index date. A date during the study
period was generated at random for every member of the study
cohort. If the random date of a study member was included in her
eligible person-time, we used her random date as the index date
and marked that woman as an eligible control. This selection
mechanism allows that the likelihood of being selected as a control
is proportional to the person-time at risk. The same eligibility
criteria were applied to controls as to cases. In total, 20000
controls were frequency-matched by age (interval of one year) and
calendar year from the list of all eligible controls.
Estimates of odds ratio (OR), assumed to be valid estimates of
the relative risk, and 95 percent confidence interval (95% CI)
associated with use of aspirin, non-aspirin NSAIDs, paracetamol,
and oral steroids compared to nonuse were computed using
unconditional logistic regression. We ascertained patients with
previous benign breast disease recorded at least more than 1 year
before the index date. Other risk factors like alcohol intake, body
mass index (BMI) and hormone replacement therapy (HRT) were
also ascertained based on their medical history recorded in the
GPRD. We also elicited subjects’ use of health services (visits to the
GP, specialist referrals and hospital admissions) in the 2 years
prior to the index date. All estimates of OR were adjusted for age,
calendar year, BMI, alcohol intake, smoking status, HRT use and
prior benign breast disease.
Exposure definition
We defined three time windows of exposure for aspirin, non-
aspirin NSAIDs, paracetamol and oral steroids: current use, past
use and nonuse. Current use was defined as use that lasted until
the index date or ended in the year prior to the index date based on
the supply of drug therapy as prescribed by the GP. Past use was
use that ended more than 1 year before the index date. Finally, the
time window of nonuse was defined as no recorded use at any time
before the index date. Current users were subdivided into short-
term and long-term users. Short-term users were patients whose
duration of treatment was shorter than 1 year and long-term users
were patients treated for a period longer than 1 year.
The effect of dose was also analysed among long-term users.
Aspirin daily dose was assigned into three groups: 75, 150 and
300mg. Specific cutoff values for each individual non-aspirin
NSAID were used to group non-aspirin NSAID daily dose into two
categories; low-medium and high dose. Daily doses of paracetamol
up to 1000mg were assigned into a low-dose category, doses above
1000mg and up to 2000mg were assigned into a medium dose
category, while doses above 2000mg were grouped into a high-
dose category. Oral steroid daily doses up to 10mg of prednisolone
(or equivalent dose for other steroids) were classified as low-
medium, while daily doses of 10mg and above were classified as
high. An additional analysis using 2 years time lag (advancing the
index date by 2 years in cases and controls) was performed.
RESULTS
The incidence rate of breast cancer in our study population was
156 per 100000 person-years among women 30–79 years old, well
in line with other reports from the UK (Office for National
Statistics, 2002).
Aspirin was associated with a decreased risk of breast cancer
(Table 1). Women taking aspirin for 1 year or longer had an OR of
0.77 (95% CI: 0.62, 0.95) compared to nonusers. The observed
effect was stronger among women using 75mg daily. The analysis
using 2 years lag time yielded similar results and current users of
aspirin for 1 year or longer had an OR of 0.81 (95% CI: 0.62, 1.06)
compared to nonusers (Table 2).
Non-aspirin NSAID use was not associated with a reduced risk
of breast cancer (Table 3). The estimate of risk among Non-aspirin
NSAID users with treatment duration longer than 1 year was 1.00
(95% CI: 0.84, 1.17). Among these women, the risk was no different
between dose groups or treatment indication groups. non-aspirin
NSAID users with at least 2 years duration presented an OR of 0.93
(95% CI: 0.76, 1.13). All these results were similar to those
observed with the 2 years lag time analysis (Table 2).
We found that paracetamol was associated with a decreased risk
of breast cancer (Table 4). The OR among women treated with
paracetamol for 1 year or longer was 0.76 (95% CI: 0.65, 0.88)
compared to nonusers. This reduced risk was observed among
low-dose and medium-dose users (OR¼0.68, 95% CI: 0.55, 0.84,
and OR¼0.73, 95% CI: 0.58, 0.91) but not among high-dose users
(OR¼1.06, 95% CI: 0.79, 1.41). The protective effect was observed
independently of the treatment indication. We also found the effect
to be similar irrespective of whether paracetamol was used alone or
in combinations. The 2 years lag time analysis provided similar
results (Table 2).
Women taking oral steroids during 1 year or longer had an OR
of 0.85 (95% CI: 0.60, 1.21) compared to nonusers. Women with
the longest duration of use (4 years or more) presented a lower risk
(OR¼0.66, 95% CI: 0.36, 1.18) (Table 5). Small numbers were
Table 1 Risk of breast cancer associated with aspirin use
Cases
(n¼3708)
Controls
(n¼20000)
Odds ratio
a
(95% CI)
Aspirin use
No use
b 3420 18260
Current use 205 1241 0.88 (0.75, 1.04)
Past use 83 499 0.90 (0.70, 1.15)
Aspirin duration
0–0.9 years 88 438 1.11 (0.87, 1.41)
1–1.9 years 37 245 0.78 (0.54, 1.13)
2–3.9 years 34 274 0.66 (0.45, 0.96)
4+ years 46 284 0.86 (0.61, 1.19)
Aspirin dose (mg)
c
75 63 498 0.67 (0.51, 0.89)
150 34 185 0.96 (0.65, 1.41)
300 20 120 0.89 (0.54, 1.46)
aAdjusted for age, calendar year, BMI, smoking, alcohol, prior benign breast disease,
NSAIDs, paracetamol, steroid and HRT use.
bReference category.
cAmong current
long-term users (1 or more years of treatment duration) vs nonusers.
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indication and dose, but we found the reduced risk to be more
apparent among high-dose users of steroids. The 2 years lag time
analysis did not affect the results (Table 2).
We studied the effect of aspirin, non-aspirin NSAIDs, para-
cetamol and oral steroids among women aged 55 years or older
and below 55 separately. The results in both age groups were
similar to the ones observed overall (data not shown).
DISCUSSION
We found that use of aspirin and paracetamol was associated with
a reduced risk of breast cancer of about 20%. On the other hand,
we found little evidence for a protective effect of non-aspirin
NSAIDs. These results are quite similar to those found in a recent
study performed with an identical design and using the same
source population that addressed the risk of another hormone-
dependent cancer in men, in this case prostate cancer (Garcı ´a
Rodrı ´guez and Gonza ´lez-Pe ´rez, 2004).
We identified 10 previous studies evaluating the association
between aspirin and breast cancer. Among them, eight reported an
estimate in line with our observed 20% risk reduction (Thun et al,
1993; Schreinemachers and Everson, 1994; Harris et al, 1996;
Table 2 Risk of breast cancer associated with aspirin, non-aspirin
nonsteroidal anti-inflammatory drugs (NSAID), paracetamol and steroid
use duration using the 2 years lag-time analysis
Cases
(n¼3708)
Controls
(n¼20000)
Odds ratio
a
(95% CI)
Aspirin
No use
b 3524 18866
Current use 122 792 0.84 (0.69, 1.02)
0–0.9 years 57 349 0.87 (0.66, 1.16)
1–1.9 years 15 124 0.65 (0.38, 1.12)
2–3.9 years 31 193 0.88 (0.60, 1.30)
4+ years 19 126 0.87 (0.53, 1.41)
Past use 62 342 0.96 (0.73, 1.26)
Non-aspirin NSAIDs
No use
b 1884 10138
Current use 802 4444 0.98 (0.89, 1.08)
0–0.9 years 606 3346 0.98 (0.88, 1.09)
1–1.9 years 62 360 0.93 (0.70, 1.23)
2–3.9 years 67 377 0.97 (0.74, 1.28)
4+ years 67 361 1.05 (0.80, 1.38)
Past use 1022 5418 1.01 (0.93, 1.11)
Paracetamol
No use
b 2244 11762
Current use 744 4345 0.88 (0.79, 0.97)
0–0.9 years 499 2760 0.92 (0.83, 1.03)
1–1.9 years 70 393 0.92 (0.70, 1.19)
2–3.9 years 87 606 0.72 (0.57, 0.92)
4+ years 88 586 0.76 (0.60, 0.97)
Past use 720 3893 0.95 (0.86, 1.04)
Oral steroids
No use
b 3452 18567
Current use 124 704 0.96 (0.79, 1.17)
0–0.9 year 96 484 1.08 (0.87, 1.35)
1–1.9 years 12 60 1.04 (0.56, 1.95)
2–3.9 years 11 70 0.93 (0.49, 1.76)
4+ years 5 90 0.31 (0.12, 0.76)
Past use 132 729 0.98 (0.81, 1.19)
aEstimates are adjusted for age, calendar year, BMI, alcohol intake, smoking status,
HRT use, prior benign breast disease, and all the variables in the table using logistic
regression.
bReference category.
Table 3 Risk of breast cancer associated with non-aspirin NSAID use
Cases
(n¼3708)
Controls
(n¼20000)
Odds ratio
a
(95% CI)
Non-aspirin NSAID use
No use
b 1563 8398
Current use 852 4465 0.98 (0.88, 1.09)
Past use 1293 7137 0.94 (0.86, 1.03)
Non-aspirin NSAID duration
0–0.9 years 611 3208 0.98 (0.87, 1.09)
1–1.9 years 84 387 1.13 (0.87, 1.47)
2–3.9 years 64 357 0.92 (0.69, 1.23)
4+ years 93 513 0.94 (0.74, 1.21)
Non-aspirin NSAID dose
c
Low-medium 128 658 0.99 (0.80, 1.23)
High 113 599 0.99 (0.79, 1.24)
Non-aspirin NSAID indication
c
OA 207 1063 0.98 (0.82, 1.17)
RA 26 145 0.96 (0.61, 1.51)
Other pain 8 49 0.84 (0.38, 1.86)
OA¼osteoarthritis, RA¼rheumatoid arthritis; NSAID¼nonsteroidal anti-inflam-
matory drugs.
aAdjusted for age, calendar year, BMI, smoking, alcohol, prior benign
breast disease, paracetamol, aspirin, steroid and HRT use.
bReference category.
cAmong current long term users (1 or more years of treatment duration) vs non-
users. Cut-off values for dose in mg were: aceclofenac 100, acemetacin 120, apazone
600, diclofenac 100, etodolac 400, fenbufen 900, fenoprofen 1200, flurbiprofen 150,
ibuprofen 1200, indomethacin 75, ketoprofen 150, mefenamic 1000, meloxicam 7.5,
nabumetone 1000, naproxen 750, piroxicam 10, sulindac 200, tenoxicam 10, and
tiaprofenic acid 450.
Table 4 Risk of breast cancer associated with paracetamol use
Cases
(n¼3708)
Controls
(n¼20000)
Odds ratio
a
(95% CI)
Paracetamol use
No use
b 1885 10040
Current use 878 4943 0.90 (0.82, 1.00)
Past use 945 5017 0.97 (0.89, 1.07)
Paracetamol duration
0–0.9 years 589 2949 1.00 (0.89, 1.12)
1–1.9 years 57 489 0.63 (0.47, 0.84)
2–3.9 years 83 531 0.81 (0.63, 1.05)
4+ years 149 974 0.77 (0.64, 0.94)
Paracetamol dose
c
Up to 1g 120 886 0.68 (0.55, 0.84)
Up to 2g 105 785 0.73 (0.58, 0.91)
More than 2g 64 323 1.06 (0.79, 1.41)
Paracetamol indication
c
OA 241 1649 0.76 (0.64, 0.89)
RA 17 112 0.78 (0.45, 1.35)
Other pain 31 233 0.70 (0.47, 1.05)
Paracetamol preparation
c
Paracetamol 48 354 0.69 (0.49, 0.95)
Paracetamol
with codeine
d
128 817 0.83 (0.67, 1.02)
Paracetamol
with propoxyphene
111 799 0.71 (0.57, 0.89)
OA¼osteoarthritis, RA¼rheumatoid arthritis.
aAdjusted for age, calendar year, BMI,
smoking, alcohol, prior benign breast disease, NSAIDs, aspirin, steroid and HRT use.
bReference category.
cAmong current long-term users (1 or more years of treatment
duration) vs nonusers.
dIncludes both codeine and dihydrocodeine.
Antiinflammatory drugs and breast cancer
LA Garcı ´a Rodrı ´guez and A Gonza ´lez-Pe ´rez
527
British Journal of Cancer (2004) 91(3), 525–529 & 2004 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yNeugut et al, 1998; Coogan et al, 1999; Harris et al, 1999;
Cotterchio et al, 2001; Johnson et al, 2002). The other two studies
found no effect (Egan et al, 1996; Anderson et al, 2002). The
summary estimate for these studies is 0.78 (95% CI: 0.70, 0.86)
(Gonza ´lez-Pe ´rez et al, 2003).
As opposed to aspirin, long-term use of non-aspirin NSAIDs was
not associated with a reduced risk of developing breast cancer in
our study. Among the four studies that previously reported an
estimate for non-aspirin NSAIDs, two of them found a negative
result (Egan et al, 1996; Johnson et al, 2002) and the other two
studies found a suggestion of a slight risk reduction (Coogan et al,
1999; Cotterchio et al, 2001). The summary estimate for these
studies is 0.89 (0.79–1.01) (Gonza ´lez-Pe ´rez et al, 2003). In our
study, the indication among long-term users of aspirin was
predominantly cardiovascular prevention. When we restricted the
analysis to women with cardiovascular comorbidity, we did not see
either any suggestion of a reduced risk among users of non-aspirin
NSAIDs (data not shown). It must be noted that in our study
recorded use of non-aspirin NSAIDs of more than 5 years was rare.
Therefore, we could not assess the effect of very extended
durations of non-aspirin NSAIDs on breast cancer occurrence
with confidence.
A reduced risk among paracetamol users has been previously
reported in two studies. Meier et al (2002)found that those with 30
paracetamol prescriptions or more had an OR of 0.8 (95% CI: 0.7,
1.0) compared to nonusers. Harris et al (1999) reported an OR of
0.84 among paracetamol users in a cohort of 32505 women.
Additionally, paracetamol has been previously linked to a
decreased risk of ovarian cancer, another hormone-related cancer
(Cramer et al, 1998; Rodriguez et al, 1998; Friis et al, 2002). In our
study, we observed that users of paracetamol presented a reduced
risk of breast cancer. However, this effect was restricted to users
taking no more than 2000mg daily, whereas users of higher doses
did not present this risk reduction. A similar pattern of dose was
observed when we looked at the effect stratified by different
treatment indications (data not shown). We found that para-
cetamol either in single or combined preparations shared the same
effect.
Previous in vitro studies have shown that glucocorticoids have a
direct inhibitory effect on proliferation of mammary cancer cells
(Goya et al, 1993). The biological mechanism is not well
understood. In fact, in normal breast tissue, glucocorticoids have
been reported to induce the synthesis of aromatase (Chen, 1998):
an enzyme that catalyses the conversion of androgens to
oestrogens, and is the target site for a new class of breast cancer
chemotherapy. However, this effect has not been observed in
cancerigenous tissue. Our results suggest that women taking oral
steroid therapy for extended duration could present a decreased
risk of breast cancer, although it should be noted that the
confidence intervals were large.
The present study has some limitations. First of all, information
on drug exposure came from prescriptions written by GPs. Over-
the-counter (OTC) use of NSAIDs, paracetamol or aspirin is
not recorded on computer files. However, the proportion of OTC
use (preferentially short-term treatment) out of the total use of
chronic treatment is small. Yet, nondifferential misclassification of
drug use due to noncompliance or OTC use would tend to
attenuate the true association between the specific drug group and
breast cancer (Ulcickas Yood et al, 2000). We could indirectly
assess the magnitude of the misclassification using data from a
study in the UK, in which subjects were interviewed to obtain
information on use of prescribed and self-medication in the last 3
months (Langman et al, 1994). In order to be able to compare
meaningfully both studies, one must take into account the
differences in the study populations. Their study, that included
both males and females, had 25% of the controls over 80 years old,
whereas our study included only females up to 79 years of age.
Prevalence of non-aspirin NSAID use in their study was 18% in the
control series, compared to 12% in our study using a similar time
window. Similarly, prevalence of paracetamol use was 20% in their
study, whereas in our study it was 16%. Since the use of most
medications (including NSAIDs and paracetamol) is greater
among elderly, it is likely that no major under-recording of
long-term NSAID or paracetamol use was present in our data after
allowing for the different age distribution. Finally, the prevalence
of aspirin was 18% in their study compared with 6% in our study.
Since our population included only women whereas theirs
included both men and women, we do expect a significantly lower
prevalence of chronic aspirin use (mainly used in cardioprophy-
laxis). Indeed, in a previous study of prostate cancer using the
same database where only males were included, we observed a
prevalence of aspirin use close to 17%. Therefore, we can also
conclude that most likely no major under-recording of long-term
aspirin use was present in our data after allowing for the different
sex and age distributions.
In some instances, a breast cancer diagnosis might be
preceded by pain symptoms and/or a greater use of health
services. This could translate into a spurious greater exposure
to pain medications among cases than controls. In order to
overcome this potential bias, we performed a 2 years lag time
analysis advancing the index date by 2 years in cases and
controls. In this secondary analysis, virtually all estimates of effect
from the main analysis were replicated. Also, adjusting for health
services utilisation (visits to GPs, specialist referrals, hospital
admissions) did not materially change the results (data not
shown).
Although we recorded information regarding traditional risk
factors for breast cancer including age, alcohol use, smoking, BMI,
HRT use and previous breast abnormalities, there is still room for
some confounding from either measurement bias or other risk
factors that we were not able to elicit such as age at menarche,
parity, family history, age at first child or germline mutation.
However, we would expect these risk factors to be rather evenly
Table 5 Risk of breast cancer associated with oral steroid use
Cases
(n¼3708)
Controls
(n¼20000)
Odds ratio
a
(95% CI)
Oral steroid use
No use
b 3370 18090
Current use 132 820 0.83 (0.68, 1.02)
Past use 206 1090 0.99 (0.84, 1.16)
Oral steroid duration
0–0.9 years 93 560 0.84 (0.66, 1.07)
1–1.9 years 9 59 0.88 (0.42, 1.80)
2–3.9 years 17 82 1.09 (0.63, 1.90)
4+ years 13 119 0.66 (0.36, 1.18)
Oral steroid dose
c
Low-medium 34 212 0.90 (0.62, 1.32)
High 5 48 0.57 (0.22, 1.47)
Oral steroid indication
c
Respiratory
disease
13 70 1.13 (0.61, 2.08)
Osteoarthritis 4 28 0.69 (0.23, 2.09)
Polymyalgia
rheumatica
8 57 0.77 (0.36, 1.65)
Rheumatoid
arthritis
9 57 0.96 (0.46, 1.99)
Other 5 48 0.53 (0.20, 1.38)
aEstimates are adjusted for age, calendar year, BMI, alcohol intake, smoking status,
HRT, aspirin, NSAID, paracetamol, and prior benign breast disease using logistic
regression.
bReference category.
cAmong current long-term users (1 or more years of
treatment duration) vs nonusers.
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consequently affecting very little, if any, our estimates of effect.
In summary, our findings suggest that use of aspirin at
cardioprophylactic doses is associated with a reduced risk of
breast cancer, but there was little evidence for a reduced risk
among users of non-aspirin NSAIDs. We also found long-term use
of paracetamol to be linked to a reduced risk of breast cancer.
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